检验医学
檢驗醫學
검험의학
LABORATORY MEDICINE
2015年
4期
314-317
,共4页
D-二聚体%慢性心力衰竭%高凝状态%血栓风险
D-二聚體%慢性心力衰竭%高凝狀態%血栓風險
D-이취체%만성심력쇠갈%고응상태%혈전풍험
D-dimer%Chronic heart failure%Hypercoagulable state%Thrombosis risk
目的:探讨血浆D-二聚体在评估慢性心力衰竭( CHF)患者血栓风险中的临床价值。方法将117例CHF患者按美国纽约心脏病协会(NYHA)分级标准分为Ⅰ级(41例)、Ⅱ级(38例)及Ⅲ级(38例)3组,以50名健康体检者作为正常对照组。采用VIDAS荧光免疫分析仪测定CHF组及正常对照组血浆D-二聚体水平。生存分析采用Kaplan-Meier曲线。采用受试者工作特征( ROC)曲线评价D-二聚体的诊断性能,采用χ2检验分析CHF患者血浆D-二聚体与临床病理因素间的关联性。结果随着CHF患者NYHA分级的增高,D-二聚体水平逐渐增高,各组间差异均有统计学意义(P<0.01),且均高于正常对照组(P<0.01)。 CHF组中发生血栓的患者D-二聚体水平明显高于未发生血栓的患者( P<0.01)。当血浆D-二聚体的临界值为2091 ng/mL时,诊断CHF患者血栓风险的敏感性为100.0%、特异性为69.0%。 CHF患者血浆D-二聚体水平与年龄、左主干病变、心肌梗死病史有关联性(P<0.01)。血浆D-二聚体>2091 ng/mL的CHF患者在90 d内发生血栓的累积概率明显增高(Log-rank χ2=59.821,P=0.000)。结论血浆D-二聚体水平与CHF多种临床病理因素相关,可反映患者病情程度,可对CHF患者血栓风险进行有效评估。
目的:探討血漿D-二聚體在評估慢性心力衰竭( CHF)患者血栓風險中的臨床價值。方法將117例CHF患者按美國紐約心髒病協會(NYHA)分級標準分為Ⅰ級(41例)、Ⅱ級(38例)及Ⅲ級(38例)3組,以50名健康體檢者作為正常對照組。採用VIDAS熒光免疫分析儀測定CHF組及正常對照組血漿D-二聚體水平。生存分析採用Kaplan-Meier麯線。採用受試者工作特徵( ROC)麯線評價D-二聚體的診斷性能,採用χ2檢驗分析CHF患者血漿D-二聚體與臨床病理因素間的關聯性。結果隨著CHF患者NYHA分級的增高,D-二聚體水平逐漸增高,各組間差異均有統計學意義(P<0.01),且均高于正常對照組(P<0.01)。 CHF組中髮生血栓的患者D-二聚體水平明顯高于未髮生血栓的患者( P<0.01)。噹血漿D-二聚體的臨界值為2091 ng/mL時,診斷CHF患者血栓風險的敏感性為100.0%、特異性為69.0%。 CHF患者血漿D-二聚體水平與年齡、左主榦病變、心肌梗死病史有關聯性(P<0.01)。血漿D-二聚體>2091 ng/mL的CHF患者在90 d內髮生血栓的纍積概率明顯增高(Log-rank χ2=59.821,P=0.000)。結論血漿D-二聚體水平與CHF多種臨床病理因素相關,可反映患者病情程度,可對CHF患者血栓風險進行有效評估。
목적:탐토혈장D-이취체재평고만성심력쇠갈( CHF)환자혈전풍험중적림상개치。방법장117례CHF환자안미국뉴약심장병협회(NYHA)분급표준분위Ⅰ급(41례)、Ⅱ급(38례)급Ⅲ급(38례)3조,이50명건강체검자작위정상대조조。채용VIDAS형광면역분석의측정CHF조급정상대조조혈장D-이취체수평。생존분석채용Kaplan-Meier곡선。채용수시자공작특정( ROC)곡선평개D-이취체적진단성능,채용χ2검험분석CHF환자혈장D-이취체여림상병리인소간적관련성。결과수착CHF환자NYHA분급적증고,D-이취체수평축점증고,각조간차이균유통계학의의(P<0.01),차균고우정상대조조(P<0.01)。 CHF조중발생혈전적환자D-이취체수평명현고우미발생혈전적환자( P<0.01)。당혈장D-이취체적림계치위2091 ng/mL시,진단CHF환자혈전풍험적민감성위100.0%、특이성위69.0%。 CHF환자혈장D-이취체수평여년령、좌주간병변、심기경사병사유관련성(P<0.01)。혈장D-이취체>2091 ng/mL적CHF환자재90 d내발생혈전적루적개솔명현증고(Log-rank χ2=59.821,P=0.000)。결론혈장D-이취체수평여CHF다충림상병리인소상관,가반영환자병정정도,가대CHF환자혈전풍험진행유효평고。
Objective To evaluate the risk of thrombosis in chronic heart failure ( CHF ) and study the clinical value by detecting the plasma D-dimer. Methods 117 CHF patients were classified into gradeⅠ(41 cases), Ⅱ(38 cases) and Ⅲ(38 cases) according to the criteria of New York Heart Association (NYHA).50 healthy subjects were included as control group .Biomerieux VIDAS fluorescence enzyme linked immunoassay analyzer was used to test the D-dimer.Kaplan-Meier curve was used to implement survival analysis , and receiver operating characteristic (ROC) curve was performed to analyze the diagnosis performance of D-dimer.χ2 test was used to analyze the relevance between D-dimer and clinical pathological factors . Results The levels of D-dimer increased with the upgrade of HYHA classification.Each group showed the statistically significant difference (P<0.01) and all were higher than the control group (P<0.01).The level of D-dimer in the thrombosis group was significantly higher than the non-thrombosis group (P<0.01).When the cut-off value of D-dimer was 2 091 ng/mL, the sensitivity was 100% and the specificity was 69% in diagnosing the risk of thrombosis in CHF .The level of D-dimer in CHF was correlated with age , the main lesions and the history of myocardial infarction (P<0.01).The cumulative probability of thrombosis within 90 days in the CHF patients whose level of D-dimer was above the cut-off value (2 091 ng/mL) increased significantly ( Log-rankχ2 =59.821, P=0.000).Conclusions The plasma D-dimer is correlated with various clinical pathological factors in CHF, which can reflect the severity of CHF disease and assess effectively the risk of thrombosis in CHF .